BR112020019579A8 - Composto, promotor de maturação de cardiomiócito, método para preparação de um cardiomiócito maduro, e, cardiomiócito maduro - Google Patents

Composto, promotor de maturação de cardiomiócito, método para preparação de um cardiomiócito maduro, e, cardiomiócito maduro

Info

Publication number
BR112020019579A8
BR112020019579A8 BR112020019579A BR112020019579A BR112020019579A8 BR 112020019579 A8 BR112020019579 A8 BR 112020019579A8 BR 112020019579 A BR112020019579 A BR 112020019579A BR 112020019579 A BR112020019579 A BR 112020019579A BR 112020019579 A8 BR112020019579 A8 BR 112020019579A8
Authority
BR
Brazil
Prior art keywords
cardiomyocyte
mature
maturation
compound
promoter
Prior art date
Application number
BR112020019579A
Other languages
English (en)
Other versions
BR112020019579A2 (pt
Inventor
Yoshida Yoshinori
Miki Kenji
Kaieda Akira
Kondo Shigeru
Nara Hiroshi
Ikeura Yoshinori
Original Assignee
Takeda Pharmaceuticals Co
Univ Kyoto
Orizuru Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Univ Kyoto, Orizuru Therapeutics Inc filed Critical Takeda Pharmaceuticals Co
Publication of BR112020019579A2 publication Critical patent/BR112020019579A2/pt
Publication of BR112020019579A8 publication Critical patent/BR112020019579A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

A presente invenção fornece um composto heterocíclico tendo uma atividade para intensificar a maturação de um cardiomiócito. Um composto representado pela fórmula (I) [em que cada símbolo é como definido na descrição] ou um sal do mesmo tem uma atividade para intensificar a maturação de um cardiomiócito e é, portanto, útil como um intensificador da maturação de cardiomiócito.
BR112020019579A 2018-03-30 2019-03-28 Composto, promotor de maturação de cardiomiócito, método para preparação de um cardiomiócito maduro, e, cardiomiócito maduro BR112020019579A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018069872 2018-03-30
JP2018-069872 2018-03-30
PCT/JP2019/013529 WO2019189553A1 (ja) 2018-03-30 2019-03-28 複素環化合物

Publications (2)

Publication Number Publication Date
BR112020019579A2 BR112020019579A2 (pt) 2021-01-12
BR112020019579A8 true BR112020019579A8 (pt) 2022-10-18

Family

ID=68059192

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020019579A BR112020019579A8 (pt) 2018-03-30 2019-03-28 Composto, promotor de maturação de cardiomiócito, método para preparação de um cardiomiócito maduro, e, cardiomiócito maduro

Country Status (15)

Country Link
US (1) US11401264B2 (pt)
EP (1) EP3778587B1 (pt)
JP (1) JP7257698B2 (pt)
KR (1) KR102708268B1 (pt)
CN (1) CN111918866B (pt)
AU (1) AU2019241702B2 (pt)
BR (1) BR112020019579A8 (pt)
CA (1) CA3095717A1 (pt)
CO (1) CO2020012101A2 (pt)
ES (1) ES2966207T3 (pt)
IL (1) IL277340B2 (pt)
MX (1) MX2020010184A (pt)
SG (1) SG11202009314XA (pt)
TW (1) TWI820104B (pt)
WO (1) WO2019189553A1 (pt)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5594003A (en) 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
DE4212748A1 (de) 1992-04-16 1993-10-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
RU2392315C2 (ru) 2003-10-03 2010-06-20 Кейити ФУКУДА Способ индукции дифференциации стволовых клеток в миокардиальные
DE502004001104D1 (de) 2004-04-10 2006-09-14 Henkel Kgaa Lockenwickler
JP5560393B2 (ja) 2005-06-22 2014-07-23 アステリアス バイオセラピューティクス インコーポレイテッド 心筋細胞系列細胞への霊長類多能性幹細胞の分化
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP3418297B1 (en) 2005-12-13 2023-04-05 Kyoto University Nuclear reprogramming factor
BRPI0710949A2 (pt) 2006-04-28 2012-03-06 Asubio Pharma Co., Ltd. Método para indução de diferenciação de células tronco pluripotentes em cardiomiócitos
US7661738B2 (en) 2006-11-28 2010-02-16 Veritainer Corporation Radiation detection unit for mounting a radiation sensor to a container crane
EP2145000A4 (en) 2007-04-07 2010-05-05 Whitehead Biomedical Inst REPROGRAMMING SOMATIC CELLS
EP2164951A2 (en) 2007-05-30 2010-03-24 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US8765465B2 (en) 2008-03-26 2014-07-01 Kyoto University Efficient production and use of highly cardiogenic progenitors and cardiomyocytes from embryonic and induced pluripotent stem cells
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
JP5930205B2 (ja) * 2010-08-26 2016-06-08 国立大学法人京都大学 多能性幹細胞の心筋分化促進剤
JP5840855B2 (ja) 2011-03-30 2016-01-06 学校法人東京女子医科大学 胚性幹細胞から心筋シートを製造する方法
JP5920741B2 (ja) 2012-03-15 2016-05-18 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
CN105247041B (zh) 2013-05-31 2018-04-20 爱心细胞有限公司 组入有水凝胶的层叠细胞膜片
EP3008172B1 (en) * 2013-06-11 2020-05-06 Ncardia B.V. Culture medium compositions for maturating cardiomyocytes derived from pluripotent mammalian stem cells
JP6651218B2 (ja) * 2014-05-30 2020-02-19 国立大学法人京都大学 低分子化合物を用いた多能性幹細胞の心筋分化誘導法
EP3219790B1 (en) 2014-11-12 2021-08-04 Terumo Kabushiki Kaisha Myocardial cell sheet
JP2017060422A (ja) * 2015-09-24 2017-03-30 国立大学法人 東京大学 成熟した心筋細胞を分化誘導させる方法
JP6702134B2 (ja) 2016-10-27 2020-05-27 トヨタ自動車株式会社 電動車両

Also Published As

Publication number Publication date
RU2020135574A (ru) 2022-05-04
JP7257698B2 (ja) 2023-04-14
CN111918866B (zh) 2023-07-04
BR112020019579A2 (pt) 2021-01-12
AU2019241702A1 (en) 2020-10-08
SG11202009314XA (en) 2020-10-29
ES2966207T3 (es) 2024-04-18
JPWO2019189553A1 (ja) 2021-03-25
CN111918866A (zh) 2020-11-10
EP3778587C0 (en) 2023-10-04
WO2019189553A1 (ja) 2019-10-03
MX2020010184A (es) 2020-10-28
KR102708268B1 (ko) 2024-09-20
TWI820104B (zh) 2023-11-01
CA3095717A1 (en) 2019-10-03
EP3778587A4 (en) 2021-10-06
TW201942354A (zh) 2019-11-01
AU2019241702B2 (en) 2023-07-27
US20210024512A1 (en) 2021-01-28
IL277340B1 (en) 2024-03-01
IL277340B2 (en) 2024-07-01
KR20200139210A (ko) 2020-12-11
CO2020012101A2 (es) 2020-12-10
EP3778587B1 (en) 2023-10-04
US11401264B2 (en) 2022-08-02
EP3778587A1 (en) 2021-02-17
IL277340A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CL2022000787A1 (es) Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
BR112019011120A2 (pt) dinucleotídeos cíclicos como agonistas de sting (estimulador de genes do interferon)
BR112018076600A2 (pt) processo para a preparação de derivado de piridona policíclica substituída e cristal do mesmo
ECSP15035343A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
BR112017002827A2 (pt) derivado de quinolina altamente puro e método para produção do mesmo
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112016013299A2 (pt) Composto
BRPI0708685B8 (pt) composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
CO2023017082A2 (es) Compuestos de tiadiazolilo unidos a un átomo de oxígeno como inhibidores de dna polimerasa θ
BR112018001869A2 (pt) método para preparação de ácidos biliares e derivados dos mesmos
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112016029825A2 (pt) composto
BR112015019276A2 (pt) compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
BR112021017336A2 (pt) Inibidores de rad51
BR112017012491A2 (pt) composição
BR112017012487A2 (pt) composição aquosa
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
BR112021023563A2 (pt) Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos
BR112022002171A2 (pt) Composto bis-amida e uso do mesmo
BR112016017423A2 (pt) Monoésteres, sais complexos internos ou sais de monoéster de ácido hexa-hidro-ss e suas aplicações como aditivos para alimentação animal
BR112015021760A2 (pt) acelerador de crescimento de planta
BR112018072039A2 (pt) composto, medicamento, método, e, uso do composto ou sal do mesmo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: ORIZURU THERAPEUTICS, INC. (JP)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]